[{"indications": "Indications\u00a0see under Dose", "name": "RIFAMPICIN Combined preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.9 Antituberculosis drugs", "RIFAMPICIN", "Combined preparations"], "cautions": "Cautions\u00a0see Monitoring in notes above; also liver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged\r\ntherapy, see also below); acute porphyria (section 9.8.2); important: effectiveness of hormonal contraceptives is reduced and alternative\r\nfamily planning advice should be offered (see also section 7.3.1); discolours soft\r\ncontact lenses; see also notes above; interactions: Appendix 1 (rifamycins)Note\u00a0If treatment interrupted re-introduce\r\nwith low dosage and increase gradually; discontinue permanently if serious side-effects developHepatic disorders\u00a0Patients or their\r\ncarers should be told how to recognise signs of liver disorder, and\r\nadvised to discontinue treatment and seek immediate medical attention\r\nif symptoms such as persistent nausea, vomiting, malaise or jaundice\r\ndevelop", "side-effects": "Side-effects\u00a0gastro-intestinal symptoms including anorexia,\r\nnausea, vomiting, diarrhoea (antibiotic-associated colitis reported);\r\nheadache, drowsiness; those occurring mainly on intermittent therapy\r\ninclude influenza-like symptoms (with chills, fever, dizziness, bone\r\npain), respiratory symptoms (including shortness of breath), collapse\r\nand shock, haemolytic anaemia, thrombocytopenic purpura, disseminated\r\nintravascular coagulation, and acute renal failure; alterations of\r\nliver function, jaundice; flushing, urticaria, and rashes; other side-effects\r\nreported include oedema, psychoses, adrenal insufficiency, muscular\r\nweakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis,\r\nStevens-Johnson syndrome, pemphigoid reactions, leucopenia, eosinophilia,\r\nmenstrual disturbances; urine, saliva, and other body secretions coloured\r\norange-red; thrombophlebitis reported if infusion used for prolonged\r\nperiod", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3918.htm", "doses": ["Brucellosis, legionnaires\u2019 disease, endocarditis and serious\r\nstaphylococcal infections, in combination with other drugs, by mouth or by intravenous infusion, 0.6\u20131.2\u00a0g daily (in 2\u20134 divided doses)", "Tuberculosis, in combination with other drugs, see notes above", "Leprosy, section 5.1.10", "Prophylaxis of meningococcal meningitis and Haemophilus\r\ninfluenzae (type b) infection, Table 2, section 5.1", "Name[Rifater\u00ae (Sanofi-Aventis) ] Tablets, pink, s/c, rifampicin 120\u00a0mg, isoniazid 50\u00a0mg, pyrazinamide 300\u00a0mg, net price 100-tab pack= \u00a321.95. \r\n    Label:\r\n    8, 14, 22, counselling, see lenses aboveDose\u00a0initial treatment of pulmonary tuberculosis, patients\r\nup to 40\u00a0kg 3 tablets daily preferably before breakfast, 40\u201349\u00a0kg\r\n4 tablets daily, 50\u201364\u00a0kg 5 tablets daily, 65\u00a0kg or more, 6 tablets\r\ndaily; not suitable for use in children"], "pregnancy": "Pregnancy\u00a0manufacturers advise very high doses teratogenic\r\nin animal studies in first trimester; risk of neonatal\r\nbleeding may be increased in third trimester; see also Pregnancy"}]